Latent IR may contribute to hyperuricemia in individuals with MHO by upregulating urate transporter 1 and glucose transporter 9 and promoting uric acid precursor accumulation through impaired glycolytic pathways [40–42]. Here, SLC22A12 is linked to hyperuricemia.